查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1797203

全球切片檢查市場

Cancer Biopsies
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 380 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球切片檢查市場規模將達到 509 億美元

全球切片檢查市場規模預計在2024年為290億美元，到2030年將達到509億美元，2024年至2030年的複合年成長率為9.8%。本報告分析的細分市場之一——儀器——預計複合年成長率為8.6%，到分析期結束時規模將達到140億美元。套件和耗材細分市場在分析期間的複合年成長率預計為8.4%。

美國市場預計將達到 79 億美元，中國市場複合年成長率將達到 13.2%

美國癌症切片檢查市場規模預計在2024年達到79億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到102億美元，在2024-2030年的分析期間內，複合年成長率為13.2%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為7.2%和8.5%。在歐洲，預計德國市場的複合年成長率為7.7%。

全球切片檢查市場—主要趨勢和促進因素摘要

為什麼癌症切片檢查對於準確診斷和個人化治療至關重要？

癌症切片檢查是現代腫瘤學中的關鍵步驟，是診斷癌症、確定腫瘤類型、分期和分級以及指導個人化治療方案的可靠方法。切片檢查包括從可疑腫塊中採集組織或細胞，然後進行顯微鏡檢查以檢測惡性程度並評估特定的分子標記。這個診斷過程不僅可以確認癌症的存在，還可以提供有關腫瘤生物學行為和基因特徵的重要資訊。隨著癌症治療日益轉向標靶治療和免疫治療，準確的切片檢查數據變得更加重要。醫生依靠切片檢查結果根據個別腫瘤特徵選擇最有效的治療通訊協定，並確保治療更合適且更成功。如果沒有切片檢查，治療決策通常僅基於影像學檢查和症狀，而這些結果可能不確定或具有誤導性。此外，切片檢查常用於監測治療反應和檢測癌症復發，使其成為長期患者管理的基石。病理學、影像引導技術和分子檢測的進步顯著提高了切片檢查的準確性和安全性。由於人口老化、生活方式改變和環境暴露，全球癌症發生率上升，透過切片檢查進行早期準確診斷的需求日益迫切，這也強化了切片檢查在癌症治療過程中不可替代的作用。

技術創新如何改變切片檢查技術和診斷準確性？

一系列技術進步正在徹底改變切片檢查領域，這些進步提高了準確性、最大限度地減少了侵入性並實現了即時診斷。其中最重要的發展之一是影像導引切片檢查技術的興起，例如超音波切片檢查、CT切片檢查和 MRI 導引切片檢查。這些方法確保收集到最具代表性的組織樣本，從而降低了操作風險並提高了診斷產量比率。另一項重大創新是液態切片，它可以分析血液和其他切片檢查中的生物標記物，例如循環腫瘤 DNA (ctDNA)、循環性腫瘤細胞(CTC) 和外泌體。這種非侵入性方法無需重複取樣即可實現早期檢測、動態監測治療反應和識別抗藥性突變。次世代定序(NGS) 和其他分子分析工具也在改變活體組織切片樣本的分析方式，可以對腫瘤進行全面的基因組圖譜繪製並發現可為精準治療提供資訊的可操作突變。機器人和人工智慧輔助切片檢查設備也開始湧現，它們提高了標靶性，並減少了操作人員的差異性。此外，數位病理學正在簡化切片檢查審查流程，促進更快的診斷、遠端會診以及跨癌症中心的數據整合。這些創新共同推動著從傳統診斷方法轉向更個人化、預測性和預防性的癌症治療模式的轉變。

影響全球切片檢查需求的區域和流行病學因素有哪些？

癌症切片檢查的需求受到當地醫療保健能力、癌症發病率模式和旨在早期發現的公共衛生舉措等多種因素的影響。在北美和歐洲，先進的醫療保健基礎設施、廣泛的癌症篩檢計畫和較高的意識層級促使切片檢查廣泛應用於各種癌症類型，包括乳癌、肺癌、大腸癌和攝護腺癌。這些地區對早期發現的重視，加上優惠的保險覆蓋和報銷機制，導致切片檢查和先進的切片檢查技術廣泛應用。在亞太地區，人口老化、吸菸率上升和生活方式改變導致的癌症發病率上升正在推動切片檢查服務的擴展。中國、印度和日本等國家正大力投資診斷基礎設施，擴大病理實驗室、影像中心和腫瘤服務的可近性。促進早期癌症檢測和行動診斷設備發展的公共衛生宣傳活動正在促進農村和服務不足地區的廣泛採用。在拉丁美洲和非洲，獲得專科醫療保健的機會有限仍然是一個挑戰，但人們正在努力透過夥伴關係、捐助者資助的舉措和政府支持的篩檢計畫來提高癌症診斷能力。這些地區的城市中心對先進診斷方法的需求日益成長，包括液態切片和分子分析。在全球範圍內，多學科癌症治療的興起以及切片檢查與數位醫療記錄的整合正在簡化診斷途徑並鼓勵早期療育干預。癌症發生率的地區差異，例如非洲和亞洲部分地區的子宮頸癌發生率高以及東南亞的肝癌熱點，也在影響切片檢查實踐和特定情況通訊協定的發展。這些趨勢表明，隨著切片檢查系統認知到活體組織切片在改善癌症預後方面的核心作用，全球切片檢查利用率將激增。

推動全球切片檢查市場擴張的關鍵因素有哪些？

切片檢查市場的成長受到多種因素的驅動，包括技術進步、流行病學趨勢、醫療保健政策和精準診斷的臨床需求。最重要的促進因素之一是全球癌症發生率的上升，這推動了對準確及時的診斷工具的需求，以確認惡性腫瘤並開始治療。由於癌症仍然是全球主要的死亡原因之一，因此無論在已開發國家開發中國家，透過可靠的切片檢查技術進行早期發現的緊迫性都在增加。細針抽吸、粗針穿刺切片和液態切片等微創和非侵入性切片檢查技術的選擇不斷擴大，正在擴大患者獲得活體組織切片的機會並降低與手術相關的風險。基因組定序、生物標記發現和即時影像方面的技術進步使切片檢查不僅能夠提供組織學數據，還能提供可指南標靶治療和個人化治療計劃的深層分子見解。對伴隨診斷和標靶藥物監管核准的日益重視與透過切片檢查進行準確的腫瘤分析的需求密切相關。在醫療支出不斷成長和基礎設施建設的支持下，醫療系統正擴大將切片檢查服務納入其篩檢計畫和癌症治療方案。此外，患者對微創、快速、精準診斷的需求，正推動醫療保健提供者採用先進的切片檢查技術。臨床研究和腫瘤臨床試驗也推動了切片檢查需求的成長，因為越來越多的研究需要採集組織樣本進行合格篩檢和療效切片檢查。總而言之，這些市場促進因素凸顯了切片檢查市場的強勁擴張及其在現代數據主導、以患者為中心的癌症治療中的關鍵作用。

部分

產品類型（儀器、套件和耗材、軟體和生物資訊學、針頭設備、真空輔助設備、導引系統）、程序（組織切片檢查、液態切片）、癌症類型（乳癌、肺癌、結直腸癌、前列腺癌、子宮頸癌、其他癌症類型）、最終用戶（醫院最終用戶、診斷實驗室最終用戶、門診手術中心最終用戶）

受訪公司範例

  • Agilent Technologies Inc.
  • ANGLE plc
  • Becton, Dickinson and Company
  • Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • Bio-Techne Corporation
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Guardant Health Inc.
  • Hologic Inc.
  • Illumina Inc.
  • Invitae Corporation
  • Johnson & Johnson（Veridex）
  • Leica Biosystems
  • Menarini Silicon Biosystems
  • Myriad Genetics Inc.
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • Veracyte Inc.

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 沒有遵循查詢 LLM 或特定產業SLM 的典型規範，而是建立了一個來自世界各地專家的精選內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP38597

Global Cancer Biopsies Market to Reach US$50.9 Billion by 2030

The global market for Cancer Biopsies estimated at US$29.0 Billion in the year 2024, is expected to reach US$50.9 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$14.0 Billion by the end of the analysis period. Growth in the Kits & Consumables segment is estimated at 8.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.9 Billion While China is Forecast to Grow at 13.2% CAGR

The Cancer Biopsies market in the U.S. is estimated at US$7.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.2 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Cancer Biopsies Market - Key Trends & Drivers Summarized

Why Are Cancer Biopsies Indispensable to Accurate Diagnosis and Personalized Treatment?

Cancer biopsies are critical procedures in modern oncology, serving as the definitive method for diagnosing cancer, determining tumor type, stage, and grade, and guiding personalized treatment plans. A biopsy involves the extraction of tissue or cells from a suspicious mass, followed by microscopic examination to detect malignancy and assess specific molecular markers. This diagnostic process not only confirms the presence of cancer but also provides essential insights into the tumor’s biological behavior and genetic profile. As cancer treatment increasingly shifts toward targeted therapies and immunotherapies, precise biopsy data is becoming even more vital. Physicians rely on biopsy results to select the most effective treatment protocols based on an individual’s tumor characteristics, ensuring that therapy is both appropriate and potentially more successful. Without a biopsy, treatment decisions would often be based on imaging and symptoms alone, which can be inconclusive or misleading. Moreover, biopsies are frequently used to monitor treatment response and detect cancer recurrence, making them a cornerstone of long-term patient management. Advances in pathology, imaging-guided techniques, and molecular testing have significantly improved the accuracy and safety of biopsy procedures. As cancer incidence rises globally, driven by aging populations, lifestyle changes, and environmental exposures, the need for early and accurate diagnosis through biopsies is growing more urgent, reinforcing their role as an irreplaceable element in the continuum of cancer care.

How Are Technological Innovations Transforming Biopsy Techniques and Diagnostic Precision?

The field of cancer biopsies is being revolutionized by a wave of technological advancements that are enhancing precision, minimizing invasiveness, and enabling real-time diagnostics. One of the most significant developments is the rise of image-guided biopsy techniques, such as ultrasound-guided, CT-guided, and MRI-guided biopsies, which allow clinicians to target tumors with exceptional accuracy, even in anatomically complex or deep-seated locations. These methods reduce procedural risks and increase diagnostic yield by ensuring that the most representative tissue is sampled. Another major innovation is the growth of liquid biopsies, which involve analyzing biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes in blood or other body fluids. This non-invasive approach enables earlier detection, dynamic monitoring of treatment response, and identification of resistance mutations, all without the need for repeated tissue sampling. Next-generation sequencing (NGS) and other molecular profiling tools are also transforming how biopsy samples are analyzed, allowing for comprehensive genomic mapping of tumors and uncovering actionable mutations that can inform precision therapies. Robotic and AI-assisted biopsy devices are beginning to emerge, offering improved targeting and reduced variability between operators. Additionally, digital pathology is streamlining the review of biopsy slides, facilitating faster diagnoses, remote consultations, and data integration across cancer centers. Together, these innovations are driving a shift from conventional diagnostic approaches toward a more personalized, predictive, and preventive model of cancer care, where biopsies not only detect disease but also guide its management with increasing sophistication.

What Regional and Epidemiological Factors Are Shaping the Global Demand for Cancer Biopsies?

The demand for cancer biopsies is influenced by a combination of regional healthcare capacities, cancer incidence patterns, and public health initiatives aimed at early detection. In North America and Europe, advanced healthcare infrastructure, widespread cancer screening programs, and high awareness levels contribute to a high volume of biopsy procedures across diverse cancer types such as breast, lung, colorectal, and prostate cancers. The emphasis on early detection in these regions, coupled with insurance coverage and reimbursement mechanisms, supports widespread use of both traditional and advanced biopsy methods. In Asia-Pacific, rising cancer incidence due to aging populations, increased smoking rates, and lifestyle transitions is driving the expansion of biopsy services. Countries like China, India, and Japan are investing heavily in diagnostic infrastructure, expanding access to pathology labs, imaging centers, and oncology services. Public health campaigns promoting early cancer detection and the development of mobile diagnostic units are improving reach in rural and underserved areas. In Latin America and Africa, limited access to specialized healthcare remains a challenge, but efforts are underway to increase cancer diagnostic capabilities through partnerships, donor-funded initiatives, and government-supported screening programs. Urban centers in these regions are seeing growing demand for advanced diagnostic modalities, including liquid biopsies and molecular profiling. Globally, the rise of multidisciplinary cancer care and the integration of biopsies into digital health records are streamlining diagnostic pathways and encouraging early intervention. Regional variations in cancer prevalence, such as higher cervical cancer rates in parts of Africa and Asia or liver cancer hotspots in Southeast Asia, are also shaping biopsy practices and the development of context-specific protocols. These trends point to a global surge in biopsy utilization, as health systems recognize their central role in improving cancer outcomes.

What Are the Key Factors Driving the Global Expansion of the Cancer Biopsies Market?

The growth in the cancer biopsies market is driven by a constellation of factors that span technological evolution, epidemiological trends, healthcare policy, and clinical demand for precision diagnostics. One of the most significant drivers is the global rise in cancer incidence, which is increasing the need for accurate and timely diagnostic tools to confirm malignancy and initiate treatment. With cancer being a leading cause of mortality worldwide, the urgency for early detection through reliable biopsy techniques is intensifying across both developed and developing nations. The expanding availability of minimally invasive and non-invasive biopsy options, including fine-needle aspiration, core needle biopsies, and liquid biopsies, is broadening patient access and reducing procedure-related risks. Technological progress in genomic sequencing, biomarker discovery, and real-time imaging is allowing biopsies to provide not just histological data but also deep molecular insights that guide targeted therapies and personalized treatment plans. The growing emphasis on companion diagnostics and regulatory approvals for targeted drugs is tightly linked to the need for precise tumor profiling via biopsies. Health systems are increasingly integrating biopsy services into screening programs and cancer care pathways, supported by rising healthcare expenditure and infrastructure development. Additionally, patient demand for less invasive, faster, and more accurate diagnostic experiences is prompting providers to adopt advanced biopsy techniques. Clinical research and oncology trials are also driving biopsy demand as more studies require tissue sampling for eligibility screening and therapeutic monitoring. Together, these drivers reflect a robust and expanding market for cancer biopsies, underscoring their foundational role in modern, data-driven, and patient-centric cancer care.

SCOPE OF STUDY:

The report analyzes the Cancer Biopsies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices, Guidance Systems); Procedure (Tissue Biopsy, Liquid Biopsy) Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Other Cancer Types); End User (Hospitals End User, Diagnostic Laboratories End User, Ambulatory Surgical Centers End User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Agilent Technologies Inc.
  • ANGLE plc
  • Becton, Dickinson and Company
  • Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • Bio-Techne Corporation
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Guardant Health Inc.
  • Hologic Inc.
  • Illumina Inc.
  • Invitae Corporation
  • Johnson & Johnson (Veridex)
  • Leica Biosystems
  • Menarini Silicon Biosystems
  • Myriad Genetics Inc.
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc.
  • Veracyte Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Cancer Biopsies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Cancer Incidence Throws the Spotlight on Timely and Accurate Biopsy Diagnostics
    • Growing Shift Toward Precision Medicine Spurs Demand for Molecularly Guided Cancer Biopsies
    • Here's the Story: How Liquid Biopsies Are Transforming Early Detection and Monitoring of Cancer
    • Expansion of Targeted Therapies Strengthens Business Case for High-Resolution Tissue Sampling Technologies
    • Technological Innovations in Image-Guided and Minimally Invasive Biopsy Techniques Drive Market Adoption
    • Increased Use of Next-Generation Sequencing (NGS) in Oncology Generates Demand for High-Quality Biopsy Samples
    • Here's How Companion Diagnostics and Biomarker Discovery Are Shaping the Future of Cancer Biopsy Testing
    • Integration of AI and Digital Pathology Enhances Speed, Accuracy, and Scalability of Biopsy Result Interpretation
    • Growing Preference for Outpatient and Ambulatory Procedures Fuels Demand for Portable and Less-Invasive Biopsy Devices
    • Rising Emphasis on Repeat Biopsies for Treatment Monitoring Expands Opportunities in Longitudinal Cancer Care
    • Public and Private Investment in Cancer Screening Programs Drives Volume Demand for Diagnostic Biopsies
    • Increased Focus on Rare and Hard-to-Biopsy Cancers Spurs Development of Novel Sampling Methods and Devices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cancer Biopsies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cancer Biopsies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Kits & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Kits & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Kits & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Software & Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Software & Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Software & Bioinformatics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Needle-based Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Needle-based Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Needle-based Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Vacuum-assisted Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Vacuum-assisted Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Vacuum-assisted Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Guidance Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Guidance Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Guidance Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diagnostic Laboratories End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Diagnostic Laboratories End User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgical Centers End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Ambulatory Surgical Centers End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Ambulatory Surgical Centers End User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospitals End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Hospitals End User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Tissue Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Tissue Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Tissue Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • JAPAN
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • CHINA
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • EUROPE
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Cancer Biopsies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • FRANCE
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • GERMANY
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Cancer Biopsies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • INDIA
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Cancer Biopsies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Cancer Biopsies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
  • AFRICA
    • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030

IV. COMPETITION